Placeholder image

Jake NunnBoard Member

Jake has more than 20 years experience in the life science industry as an investor, research analyst and investment banker. Jake joined New Enterprise Associates (NEA) in 2006 as a Partner where he focuses on later-stage specialty pharmaceuticals, biotechnology and medical device investments and manages a number of NEA’s public investments in healthcare. Jake is a Director of Dermira (Nasdaq: DERM) and Trevena, Inc. (Nasdaq: TRVN). He previously was a Director of Hyperion Therapeutics (acquired by Horizon Pharma PLC), TriVascular (acquired by Endologix), Aciex Therapeutics (sold to Nicox SA) and Transcept Pharmaceuticals (merged with Paratek). Prior to NEA, Jake worked at MPM Capital as a Partner with the MPM BioEquities Fund, where he specialized in public, PIPE and mezzanine-stage life sciences investing. Previously, he was a healthcare research analyst and portfolio manager at Franklin Templeton Investments. Jake was also an investment banker with Alex. Brown & Sons. He received an MBA from the Stanford Graduate School of Business and an AB in Economics from Dartmouth College. Jake holds the Chartered Financial Analyst designation, and is a member of the CFA Society of San Francisco